The ability of transient immunosuppression with a combination of a non-depleting anti-CD4 (NDCD4) antibody and cyclosporine (CyA) to abrogate immune reactivity to both adeno-associated viral vector (AAV) and its transgene product was evaluated. This combination of immunosuppressants resulted in a 20-fold reduction in the resulting anti-AAV8 antibody titres, to levels in naïve mice, following intravenous administration of 2Â10 12 AAV8 vector particles per kg to immunocompetent mice. This allowed efficient transduction upon secondary challenge with vector pseudotyped with the same capsid. Persistent tolerance did not result, however, as an anti-AAV8 antibody response was elicited upon rechallenge with AAV8 without immunosuppression. The route of vector administration, vector dose, AAV serotype or the concomitant administration of adenoviral vector appeared to have little impact on the ability of the NDCD4 antibody and CyA combination to moderate the primary humoral response to AAV capsid proteins. The combination of NDCD4 and CyA also abrogated the humoral response to the transgene product, that otherwise invariably would occur, following intramuscular injection of AAV5, leading to stable transgene expression. These observations could significantly improve the prospects of using rAAV vectors for chronic disorders by allowing for repeated vector administration and avoiding the development of antibodies to the transgene product.
INTRODUCTION
Recombinant adeno-associated viral vectors (AAVs) show great promise for gene therapy of a variety of different genetic disorders including haemophilia B, lysosomal storage disorders, inherited retinal degeneration, a-1 antitrypsin and lipoprotein lipase deficiency. [1] [2] [3] [4] [5] [6] [7] In addition to their excellent safety profile, the greatest attribute of these vectors is their ability to mediate persistent therapeutic transgene expression following a single administration of vector in a variety of animal models. 1, 2, [8] [9] [10] The majority of the transgenic protein is expressed by episomally retained double-stranded genomes that persist in post-mitotic tissues in a variety of forms, including concatemers, by hitherto unknown mechanisms. [11] [12] [13] This has favourable safety implications with respect to insertional mutagenesis but raises the possibility that transgene expression will decline overtime with the natural turn over of the transduced cells. Indeed, we have observed gradual decline in transgene expression in a proportion of rhesus macaques at approximately 3-5 years after liver-targeted delivery of AAV. 14 Therefore, for chronic disorders such as haemophilia B, repeated administration of rAAV vectors may become necessary to maintain expression of human Factor IX (hFIX) within therapeutic levels. However, serotype-specific antibodies directed towards the viral capsid proteins, generated following primary vector administration, will prevent efficient gene transfer with rAAV of the same serotype. [14] [15] [16] [17] [18] Although we have demonstrated the feasibility of using vector particles of different serotypes for vector readministration, this strategy does not permit the use of 'vector of choice' more than once because of the generation of a humoral immune response. This is of concern for lifelong disorders as there are a limited number of serotypes that are suitable for optimal transduction of target tissues, such as the liver, each with serotype-specific differences in tropism, seroprevalence rates and production methodology. 14, 16, 19 An alternative, potentially more practical approach that may allow for effective readministration of rAAV of the same serotype involves the use of transient immunosuppression at the time of vector administration. The goal with this strategy would be to attenuate the development of serotype-specific neutralizing rAAV antibodies without inducing permanent tolerance. A large body of data suggests that T cells have a central role in the development of a humoral response by B lymphocytes following AAV-mediated gene transfer. [20] [21] [22] [23] However, moderation of T-cell function with conventional immunosuppressive agents such as the calcineurin inhibitor cyclosporine (CyA) cannot avert a humoral response to rAAV. 17 Hence, the focus has turned to more refined targets such as the CD40-CD40 ligand and CD28-CD80/86 co-stimulatory pathways. 22, 23 Indeed, cytotoxic T-lymphocyte-associated antigen-4 immunoglobulin (CTLA4Ig), which blocks the binding of CD80/86 to CD28 on T-lymphocytes when combined with a neutralizing antibody against the CD40 ligand, impaired the ability of mice to mount a humoral response to AAV delivered to the lungs, allowing effective readministration of vector of the same serotype. 17 Although lungs are an immunologically distinct compartment, it is likely that this type of approach will be effective following systemic administration of AAV, based on the success with adenoviral vectors in murine and non-human primate models. 24, 25 However, the clinical use of anti-CD40L antibody, a critical component of this immunosuppressive combination, is limited by its thrombogenic properties. 26 The CD4 + T-cell population is another key target for mediating immunological hyporesponsiveness because of its interactions with both cytotoxic-B and cytotoxic-T lymphocytes. Depleting CD4 antibodies have been shown to induce tolerance in the setting of allogeneic transplant and inhibit primary humoral responses to viral capsid proteins in animal models. 21 However, their use in the clinic has been restricted by the occurrence of prolonged immunosuppression as a result of CD4 T-cell depletion. In contrast, non-depleting CD4 antibodies (NDCD4ab) induce long-term antigen-specific tolerance to foreign antigens without causing depletion of CD4 lymphocytes by resetting the immunological balance through the deletion of alloreactive T-cells while facilitating the selective expansion or survival of regulatory T-cells (T-regs). 27 Therefore, transient CD4 receptor blockade at the time of vector administration may offer several advantages for gene therapy of haemophilia with rAAV vectors, including:
(1) dampening of the humoral response to viral capsid and (2) prevention of inhibitor formation after gene transfer, which is a serious complication of protein concentrate therapy. However, CD4 co-receptor blockade has not been extensively evaluated in the context of AAV-mediated gene transfer for gene therapy of haemophilia B.
In this study, we show that CyA and NDCD4ab, when co-administered with rAAV vectors, prevent a primary humoral response to capsid proteins enabling successful gene transfer upon readministration of vectors based on the same serotype without causing tolerance to viral proteins. This combination of immunosuppressive agents also facilitated the development of immunological tolerance to the hFIX transgene following intramuscular delivery of AAV, resulting in stable long-term expression of hFIX. Importantly, immunosuppression was only required transiently at the time of vector administration and did not cause lymphodepletion, which is an important safety consideration for patients with chronic disorders such as haemophilia.
RESULTS

Attenuation of humoral response against AAV8 following transient immunosuppression
In our initial experiments, we determined if the humoral response to a primary exposure of AAV8 could be modulated as this serotype shows great promise for liver-targeted gene therapy. We used our previously described self complementary AAV vector that contains the hFIX cDNA under the control of a liver-specific promoter (scAAV2/8-LP1-hFIXco) pseudotyped with AAV8 capsid protein. 16 As described in the experimental schema in Figure 1a , six groups of 6-8-weeks-old male C57Bl/6 immunocompetent mice received a single tail vein administration of 2Â10 12 vg kg À1 of scAAV2/8-LP1-hFIXco concomitantly with NDCD4ab (20 mg kg À1 per mouse, intraperitoneally alone or in combination with either CyA (25 mg kg À1 per mouse, intraperitoneally) or mycophenolate mofetil (MMF, 20 mg kg À1 per mouse, intraperitoneally) on days À1, 0, +1, +3, +6 and +8 with respect to vector administration on day 0. For comparison, cohorts of scAAVtransduced mice were treated with CyA or MMF alone along the same schedule. The positive control group consisted of mice transduced with scAAV in the absence of immunosuppression. The negative control group consisted of mice that had not been exposed to scAAV vector or immunosuppression. The dose of AAV selected for these studies is sufficient to mediate hFIX expression in mice and nonhuman primates at levels that would be therapeutically relevant in haemophilia-B patients (45% of normal levels). 3, 16, 28 Immunosuppression was well tolerated with no overt evidence of toxicity. In agreement with previously published data in rodents, nonhuman primates and humans, the NDCD4ab did not induce lymphopenia as illustrated by flow cytometric analysis of CD3 and CD4 levels using antibodies that target epitopes that are distinct from that used by the NDCD4ab (Figure 1b) . [29] [30] [31] [32] CD4 + CD25 + FoxP3 + T cells numbers in the spleen of NDCD4ab-treated cohort were equivalent to the numbers seen in naïve animals. The kinetics of hFIX expression was similar in each of the scAAV2/8-LP1-hFIXco transduced cohorts with mean steady-state plasma levels of approximately 40% of normal ( Figure 1c ). This level of transgene expression is consistent with that previously reported with this vector dose, suggesting that scAAVmediated transduction in C57BL/6 mice is not influenced by concurrent administration of immunosuppressive agents. 16 The magnitude of the anti-AAV8 humoral immune response in the cohorts treated with single agent CyA (63±21 relative units (RU) ml À1 ) and MMF (61 ± 19 RU ml À1 ) as determined by an AAV8-specific immunocapture assay was lower but not statistically different (P¼0.31 and 0.27, respectively) from that in the positive control group (90 ± 10 RU ml À1 ), which was transduced with scAAV in the absence of immunosuppression. In contrast, the anti-AAV8 antibody titres were significantly reduced in mice transduced with scAAV2/8-LP1-hFIXco (11±2 RU ml À1 ) in the presence of NDCD4ab alone (P¼0.007). Combining MMF with NDCD4ab did not cause a further reduction in the humoral response (12±3 RU ml À1 ) to the AAV capsid protein. However, the lowest anti-AAV8 antibody titres were observed in the cohort of mice treated with a combination of CyA and NDCD4ab with mean levels of 3 ± 1 RU ml À1 . These levels were comparable to background anti-AAV8 antibody titres (2.5 ± 1 RU ml À1 ) in negative control animals that had not been exposed to AAV (Figure 1d) . A surprising aspect of these results was that an additive effect was observed when NDCD4ab was combined with CyA but not MMF especially as the latter, through the inhibition of inosine monophosphate dehydrogenase, affects both B-and T-lymphocyte function. 33, 34 These observations were not vector stock or mouse strain specific as they were reproducible in the Balb/c immunocompetent mice using a different stock of vector (data not shown).
Transient immunosuppression allows effective transduction upon re-administration of vectors pseudotyped with the same capsid protein Three months after primary vector exposure, the mice were challenged with a second AAV8 vector (dose¼2Â10 12 vg kg À1 ) containing the human interferon b (hIFNb) gene under a constitutively active promoter (rAAV2/8-CAGG-hIFNb) without immunosuppression. Importantly, hIFNb does not crossreact with the murine IFN receptor and the context of these experiments simply served as a secretable marker of transduction. 35 As shown in Figure 2a , efficient transduction with rAAV8-CAGGhIFNb was observed only in the cohort of mice treated with the combination of NDCD4ab and CyA at the time of primary vector administration. The level of hIFNb in these animals was 13±2 mg ml À1 and comparable to that observed in mice whose primary exposure to AAV consisted of rAAV8-CAGG-hIFNb (16 ± 1 mg ml À1 ). Successful gene transfer with the second AAV vector (rAAV2/8-CAGG-hIFNb) did not affect expression from the first vector as the expression of hFIX remained at approximately 40% (2237±49 ng ml À1 ) on day 110 following administration of scAAV2/ 8-LP1-hFIXco.
Liver is preferentially transduced after tail vein administration of AAV vectors. 1 Therefore, transduction of this organ following challenge with rAAV8-CAGG-hIFNb was assessed at a molecular level using a semi-quantitative PCR assay. 35, 36 As shown in Figure 2b , the hFIX provirus was detectable in the liver of animals exposed to scAAV2/8-LP1-hFIXco with a rough correlation between the transgene copy number and plasma hFIX level in individual animals. Among the animals that received rAAV2/8-CAGG-hIFNb as a secondary challenge, the hIFNb transgene was detected only in the NDCD4ab+CyA cohort. The hIFNb transgene copy number in these animals was similar (mean 2.2Â10 À3 copies per cell) to that observed in mice whose only exposure to AAV8 was rAAV8-CAGG-hIFNb (3.7Â10 À3 copies per cell).
In all cohorts, the total anti-AAV8 antibody levels increased following administration of rAAV2/8-CAGG-hIFNb (Figure 2c ). The level of anti-AAV8 antibody titre in the NDCD4ab+CyA cohort was similar to that in mice exposed to rAAV2/8-CAGG-hIFNb in the absence of immunosuppression. Therefore, these data suggest that transient immunosuppression with NDCD4ab+CyA combination at the time of primary exposure to AAV8 significantly attenuates humoral immunity to levels that allow efficient transduction upon re-exposure to vectors based on the same serotype (secondary challenge) in the absence of immunosuppression. Importantly, transient immunosuppression at the time of primary exposure does not lead to permanent tolerance to AAV capsid protein as illustrated by an increase in anti-AAV8 antibody titres upon secondary challenge. Indeed, when these mice were challenged again with AAV8 vector, this time encoding the human coagulation factor X (5Â10 11 vg kg À1 scAAV2/8-LP1-hFX) gene, transduction was completely blocked as illustrated by an absence of detectable human FX in plasma of animals transduced with (Figure 2d ). Transgene expression mediated by the first (scAAV2/8-LP1-hFIX) and second (rAAV2/8-CAGG-hIFNb) AAV vectors was, however, unaffected by the administration of the third vector in the NDCD4ab+CyA cohort of mice with steady state hFIX and hIFNb levels of (2098±83 ng ml À1 ) and (11±4 mg ml À1 ), respectively.
Immunosuppression can block humoral immune response to wild-type AAV2 In the next set of experiments, the immunomodulatory properties of the NDCD4ab and CyA were further assessed in a more stringent assay, in the context of wt AAV2 infection administered with adenovirus, to facilitate replication of wt AAV as well as serving as an immunological adjuvant. 4Â10 12 vg kg À1 per mouse of wt AAV2 was administered into the tail vein of 6-to 8-week-old male immunocompetent Balb/C mice either alone or in combination with an E1-E3 deleted adenoviral vector encoding green fluorescent protein (GFP) (rAd5-CMVGFP, 4Â10 12 vg kg À1 per mouse). These animals were treated concomitantly with a combination of NDCD4ab and CyA along the schedule described earlier. As shown in Figure 3 , the relative anti-AAV2 antibody titres were at least twofold higher in the cohort that received wt AAV2 together with rAd5-CMVGFP when compared with mice that received wt AAV2 alone. The concurrent administration of NDCD4ab and CyA at the time of primary infection with wt AAV2 and rAd5-CMVGFP resulted in a 15-fold reduction in anti-AAV2 titre to values observed in negative control animals that had not been exposed to AAV2 or adenovirus. The anti-AAV2 capsid antibody titres determined by serotype-specific enzyme-linked immunosorbent assay correlated directly with the results of neutralizing antibody assay (data not shown). Hence, the combination of NDCD4ab and CyA also appears to be effective at attenuating humoral immunity to AAV capsid proteins in an environment that may facilitate replication of wt AAV2 in addition to being associated with inflammation that invariably follows administration of early generation adenoviral vectors, neither of which occurs when using recombinant AAV alone.
Effect of NDCD4ab and CyA on humoral response to the transgene We and others have previously shown that intramuscular administration of AAV2 or AAV5 vectors encoding hFIX is associated with a humoral but not a cytotoxic T-cell immune response to the transgene. 1,37,38 This has not been clearly shown with AAV8 vectors, which have distinct biological properties. 14 Therefore, in the next set of experiments, 4Â10 11 vg kg À1 of AAV vectors pseudotyped with serotype 5 encoding hFIX under the control of the constitutively active CAGG enhancer-promoter element (CAGG-hFIX) was administered into the hind limb muscle of Balb/C mice together with NDCD4ab and CyA along the schedule described in Figure 1 . The positive control group consisted of animals transduced with AAV in the absence of immunosuppression. Within 4 weeks of intramuscular administration, animals transduced with AAV2/5-CAGG-hFIX in the absence of immunosuppression developed anti-hFIX antibodies (Figure 4c ), which abrogated transgene expression (Figure 4a ). These animals also had high titres of anti-AAV5 antibodies (115 ± 4 RU ml À1 ). In contrast, transient immunosuppression with a combination of NDCD4ab and CyA at the time of intramuscular administration of AAV2/5-CAGG-hFIX averted the generation of a humoral immune response to the hFIX transgene as well as the capsid protein (Figures  4b and c) . Stable expression of hFIX at an average of 2% (111 ± 9 ng ml À1 ) of normal levels was observed in this group of animals for the duration of the study (6 months). As immunocompetent mice are not tolerant to the non-species-specific hFIX antigen, we injected recombinant hFIX (Benefix 2500 IU kg À1 , Wyeth, Maidenhead, UK) into the muscle at 3 months after gene transfer to determine if peripheral tolerance can be broken. The anti-hFIX antibody titres in animals treated with rAAV2/5-CAGG-hFIX increased from 9.89 ± 3 to 36 ± 1 RU but remained unchanged in 
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mice conditioned with a combination of NDCD4ab and CyA at the time of intramuscular administration of rAAV2/5-CAGG-hFIX (1.5±0.3 and 1.8±0.7 pre and post Benefix, respectively). As described earlier, anti-hFIX antibodies were detectable in naive animals not treated with AAV. Real-time quantitative PCR analysis confirmed that the transcription of the transgene was limited to the muscle as the hFIX mRNA could not be detected in any other tissue, including the liver. As with the intravenous route, repeated intramuscular administration of 4Â1011 vg kg À1 of rAAV-CAGG-hFIX vector pseudotyped with serotype 5 capsid protein at 2 months after primary exposure but this time without immunosuppression, resulted in efficient transduction and a rise in plasma hFIX to an average of 3.6% (180±12 ng ml À1 ) normal level in the cohort of mice that received serotype 5 capsid pseudotyped rAAV concurrently with NDCD4ab and CyA but not in mice previously transduced with rAAV2/5-CAGG-hFIX vector alone.
Importantly, there was no evidence of T-cell infiltration in the muscle of any of the mice treated with rAAV2/5 CAGG-FIX, irrespective of whether they received immunosuppression. We next determined the frequency of AAV capsid-specific T cells in splenocytes using an IFN-g enzyme-linked immunosorbent spot assay following stimulation with whole AAV5 capsid for 24 h. As a positive control, the cells were incubated with phorbol myristate acetate while the negative control involved incubation of the splenocytes with medium alone. AAV capsid-specific T cells were not detected in mice that had not been exposed to AAV5 vector. In contrast, T cells reacting to AAV5 capsid were detectable at 137 ± 20 SFU per 10 6 lymphocytes following administration of AAV2/5-CAGG-hFIX. Transient immunosuppression with a combination of NDCD4ab and CyA at the time of intramuscular administration of AAV2/5-CAGG-hFIX substantially reduced the frequency of AAV capsid-specific T cells following AAV administration to levels observed in untransduced mice ( Figure 5 ). As with AAV capsid protein, hFIX-reactive T cells were detectable above background levels in mice transduced with AAV5 without immunosuppression.
DISCUSSION
Modulation of the immune response at the time of primary exposure to AAV has significant appeal for gene therapy of chronic disorders such as haemophilia. Our study demonstrates that a short exposure to NDCD4ab and CyA, at the time of vector administration, efficiently inhibited a primary humoral response to the AAV capsid proteins without any toxicity. This enabled efficient transduction following secondary challenge with vectors based on the same serotype to the level observed in mice not previously exposed to AAV8. Blockade of the humoral response, following transient immunosuppression, was independent of the route of vector administration (observed with both systemic and intramuscular route), AAV serotype, mouse strain or the concomitant administration of an early generation adenoviral vector capable of serving as an immunological adjuvant. Although further validation of these results in a context relevant to humans is essential, to our knowledge this is the first illustration of efficient transduction of the liver in immunocompetent hosts following sequential administration of rAAV vectors based on the same serotype. This is highly relevant for somatic gene therapy with AAV of chronic disorders affecting the liver, such as haemophilia, as it offers an opportunity to improve expression with repeated administration of the vector of choice in the event that transgene expression declines overtime due to the loss of the episomally retained rAAV genome as a result of the natural turn over of hepatocytes.
It is unknown based on our data if a short course of NDCD4ab and CyA would be sufficient to dampen the re-call cytotoxic T-cell response of the type recently observed in haemophilia-B patients following liver-targeted delivery of AAV-2. 3 This phenomenon has not been satisfactorily reproduced in animal models making it difficult to critically evaluate the effectiveness of immunosuppressive strategy. However, our study shows that co-receptor blockade can reduce the number of capsid-specific T cells present in the spleen and lymph node compartment. Furthermore, transient immunosuppression with NDCD4ab and CyA prevents the formation of neutralizing anti-hFIX antibodies (or inhibitors) following intramuscular delivery of rAAV. The development of neutralizing antibodies to the transgene following AAV-mediated gene transfer in patients with severe haemophilia B would represent a serious adverse event that would render these subjects unresponsive to recombinant protein replacement therapy. Although subjects recruited to our ongoing Phase I/II gene therapy trials with AAV vectors will have attained a degree of tolerance to hFIX through years of exposure to recombinant protein, there is still a theoretical risk of provoking a neutralizing hFIX antibody response following gene transfer because endogenously expressed transgene product is processed in an immunologically distinct manner when compared with infused protein concentrates.
This dual property of NDCD4ab and CyA combination gives it an important advantage over previous regimens containing cyclophosphamide, which block inhibitor formation without altering the immunological response to capsid proteins. 39 Elegant studies by Miao et al. have shown that transient blockade of the inducible CD28/CTLA4 with a combination of CTLA4Ig and an anti-murine CD40L antibody or single agent anti-inducible costimulator antibody resulted in long-term tolerance to human factor VIII after non-viral gene transfer into haemophilia-A mice. 40, 41 As blockade of the costimulatory pathway has allowed successful readministration of adenoviral vectors, we would speculate that inducible costimulator alone may be sufficient to dampen down the humoral response to capsid and transgenic proteins, but this needs to be formally established. 25 Recently, Wang et al. demonstrated long-term expression of dystrophin in a canine model of muscular dystrophy when AAV-6 vector encoding the canine micro-dystrophin gene was administered intramuscularly together with 16 weeks of immunosuppression with a combination of anti-thymocyte globulin (ATG) CyA and MF. The effects of this protracted regimen on capsid-mediated immune response are unclear but withdrawal of immunosuppression was followed by patchy T-cell infiltration of the muscle. 42 ATG has become an important component of transplant conditioning in humans but it causes prolonged lymphopenia, which is associated with an increased risk of infection. Liver-targeted delivery of rAAV concurrent with a combination of MMF and sirolimus in non-human primates resulted in partial reduction in anti-AAV2 capsid antibody titre and prevention of inhibitors to hFIX. 43 However, when daclizumab was added to this regimen, the magnitude of the humoral response to the AAV2 capsid and hFIX proteins increased dramatically to levels that were higher than the cohort of macaques that received vector without immunosuppression due to depletion of the CD4 + CD25 + FoxP3 + T-regs. This indicates that careful selection of immunosuppressive agents is necessary.
The studies described in this report were designed to establish proof-of-concept that CD4 receptor blockade can result in a hyporesponsive/tolerant state to the viral capsid and transgenic proteins. The immunological mechanisms by which NDCD4ab exerts its effects have already been extensively studied by our group in a variety of different settings. 27, 29, [44] [45] [46] Based on these published data, we hypothesize that NDCD4ab-mediated receptor blockade leads to induction of antigen-specific CD4+ T-regs following rAAV-hFIX-mediated gene transfer. Continuous expression of hFIX within the muscle bed allows the persistence of these T-regs and down-modulation of the activity of effector T-cells resulting in tolerance to hFIX protein. In contrast, viral capsid proteins are present for a brief period after vector administration thereby reducing the scope for long-term tolerance through antigen-mediated persistence of AAV capsid-specific T-regs. This result is in fact the desirable outcome as long-term tolerance to an AAV vector would render patients unable to mount an appropriate immune response to infection by wild type-AAV (wt-AAV), which is endemic among humans. An alternative explanation, suggested by recent studies, is that functional tolerance induced by antigens expressed in the muscle may result from upregulation of the programmed death-1 molecule that leads to ignorance of CD4 + T-cells and blockade of the cytotoxic function of antigen-specific CD8 + T-cells. 47, 48 Further studies are required to fully understand the mechanisms by which blockade of NDCD4ab co-receptors achieves the hyporesponsive/tolerant state but these should be conducted in a context relevant to humans. NDCD4ab has been shown to be safe in healthy human volunteers but needs to be tested further in combination with CyA in relevant non-human primate models prior to use in the clinic. 32 Our previous studies suggest that the chimpanzee and baboon models may be the most suitable for these studies as they are the only non-human primate species to show binding affinity of NDCD4ab that is comparable to humans. 31 These studies are warranted as our data in mice suggest that NDCD4ab combined with CyA is capable of attenuating immunological response to the vector capsid and transgenic proteins, which are currently the two major obstacles to stable transgene expression following AAV-mediated gene transfer to the liver.
MATERIALS AND METHODS
AAV and adenoviral vector production and purification
The CAGG-FIX, CAGG-IFNb and LP1-hFIXco plasmids have been described earlier. 16, 35, 36 rAAV-hX consisted of the full-length 1.5 kb human FX cDNA under the control of the LP1 promoter and flanked by AAV2 ITRs. The production of rAAV and scAAV vectors pseudotyped with capsid from alternative serotypes has been previously described. 14, 16 In brief, an adenoviral helper plasmid and chimeric AAV2 Rep-2Cap, -5Cap or -8Cap packaging plasmids were used to generate AAV-2, -5 and -8 pseudotyped vector particles. [49] [50] [51] The vector stocks were purified using column chromatography as previously described. 1, 52 Vector genome (vg) titres were determined by qPCR method using linear plasmid DNA as standards. The purified vector stocks were consistently free of contamination with wt-AAV and cellular and adenoviral proteins as judged by our previously described methods. 1,52 Adenoviral vector rAd5-CMVGFP was prepared as described previously. 53 Animal studies and bio-assays All procedures were performed under the authority of the UK Home Office Project and Personal Licenses regulations and in compliance with the guidelines of the University College London ethical review committee. C57Bl/6 and Balb/c immunocompetent mice were obtained from Charles Rivers or Harlan Laboratories (Blackthorn, UK). Tail vein administration of AAV and adenoviral vector particles was performed as described earlier. 14, 16 Blood samples were collected at regular intervals and assayed for the appropriate transgene (hFIX hFX or IFNb) by the enzyme-linked immunosorbent assay. Methods for detection of hFIX and IFNb have been described earlier. 1, 35 Human FX levels in mouse plasma were assessed using a complement pair of goat anti-human FX (Quadratech, Epsom, UK). For intramuscular injections, the mice were anaesthetized with isoflurane and then AAV was injected at a maximum volume of 30 ml per site directly into the quadriceps and tibialis anterior muscle, which were accessed through a 1 cm incision in the hind limb. MMF (Roche, Welwyn Garden City, UK) 20 mg kg À1 per mouse, CyA (Sandimmune, Sandoz, Holzkirchen, Germany) 25 mg kg À1 per mouse, human CTLA4Ig (Bristol-Myers Squibb, Princeton, NJ, USA) 5 mg kg À1 per mouse and NDCD4 (YTS 177.9.6.3.3F4) 20 mg kg À1 per mouse were injected intraperitoneally on days À1, 0, +1, +3, +6 and +8 with respect to AAV administration. 46 Effect of immunosuppression on cell surface markers was evaluated using flow cytometry. In brief, citrated blood was treated with four volumes of cold lysis buffer (155 mM ammonium chloride, 10 mM sodium bicarbonate, 0.1 mM EDTA) to lyse erythrocytes. The leucocytes were then washed in phosphate buffered saline and then stained with anti-mouse CD3-PE (clone 145-2C11 BD Bioscience, Oxford, UK) and CD4-FITC (YTS 3.1) for 1 h before washing and subsequent analysis on the Epics-Elite flow cytometer (Beckman-Coulter, High Wycombe, UK).
To determine rAAV transduction at a molecular level, at 4 weeks after the second AAV administration two mice were culled from each cohort. DNA was extracted from the liver. 250 ng of DNA was subject to PCR for FIX (forward 5¢-TTTCCTGATGTGGACTATGT-3¢, reverse 5¢-TCATGGAAGCCAGCACAGA ACATG-3¢), IFNb (forward 5¢-CTGTTGTGCTTCTCCACTACAG-3¢, reverse 5¢-GCCTTCAGGTAATGCAGAATCC-3¢) and b-actin (forward 5¢-TGAC GGGGTCACCCACACTGTGCCCATCTA-3¢, reverse 5¢-CTAGAAGCATTTGC GGTGGACGATGCAGGG-3¢).
An immunocapture assay was used to detect anti-AAV-specific antibodies in murine plasma as described earlier. 1 Results were expressed as the end-point titre, defined as the reciprocal of the interpolated dilution with an absorbance value equal to five times the mean absorbance background value. Neutralizing antibody titres were assessed by determining the ability of murine serum to inhibit transduction of 293T cells by pseudotyped scAAV vector containing the enhanced GFP cDNA under the control of the CMV promoter (scAAV CMV-GFP) as previously described. 2, 54 The neutralizing antibody titre is expressed as the dilution that inhibited transduction of 293 T cells by 50%. hFIX antibodies and was determined as described earlier. 1 The frequency of AAV capsid-or hFIX-specific T cells in splenocytes was determined using an IFN-g enzymelinked immunosorbent spot assay (R&D systems) according to the manufacturer's instructions. In brief, plates were blocked with media prior to loading between 1-5Â10 5 splenocytes per well and then stimulated with rAAV2/5 CAGG-FIX vector at a multiplicity of infection of 2Â10 3 , FIX 5 mg ml À1 or phorbol myristate acetate 1 ng ml À1 for 24 h at 37 1C. Spots were counted with an enzyme-linked immunosorbent spot reader (AID, Strassberg, Germany) with intensity 410, size420 and gradient45.
The probability of statistical differences between experimental groups was determined by one-way ANOVA and paired Student's t-test using GraphPad Prizm version 4.0 software (GraphPad, San Diego, CA, USA).
